New drug comb may lengthen ovarian cancer survival

	Tweet

"Major progress” has been achieved in developing chemotherapy combinations to prolong life in patients with ovarian cancer, according to a team of researchers in Greece, the UK, and the US. The top contender appears to be a combination of two types of cancer drugs—platinums and taxanes—administered intraperitoneally (directly into the abdominal cavity).

“Distinct incremental changes” have occurred in the treatment of ovarian cancer over the last four decades, Dr. John P. A. Ioannidis, of the University of Ioannina School of Medicine in Greece, and his colleagues note. Still, the exact extent of survival benefit has yet to be quantified, which must be known to weigh the pros and cons of treatment.

Therefore, Ioannidis and his associates conducted a search of published studies of ovarian cancer that enrolled five or more patients. Altogether, 60 trials published between 1971 and 2006 compared different chemotherapy combinations and reported survival data for 15,609 patients.

During the 1970s, the available ovarian cancer drugs were cisplatin, paclitaxel, cyclophosphamide, doxorubicin, carboplatin and paclitaxel, the investigators note.

Platinum-based combinations prevailed in the 1980s and 1990s.

And since the beginning of the millennium, platinum and taxanes have been the most successful treatment, which provides even better survival when administered intraperitoneally.

Before platinum and taxanes were available, chemotherapy was no better than supportive care, the authors note.

Ioannidis and his team found that a combination of platinum and taxane administered intraperitoneally “can reduce the risk of death by 55 percent.” Without effective treatment, the average survival is 2.5 years, but about 3 years are gained when the most effective combination is used.

If major progress is to made in treating ovarian cancer, the investigators note, researchers need to cooperate to develop complementary trials, decrease duplication and conduct trials together when appropriate. They say this is especially important as new drug combinations come along.

SOURCE: Journal of the National Cancer Institute, November 15, 2006.

RELATED STORIES:
Researchers Identify Ovarian Cancer Biomarkers   Finding ovarian cancer fast may not help survival   Body cavity drugs cut ovarian cancer death risk   Women often opt to surgically remove their breasts, ovaries to reduce cancer risk   Blood test detects ovarian cancer early   Researchers Find Ovarian Cancer Risk Related To Inherited Inflammation Genes   Physical activity does not ward off ovarian cancer   Drinking Tea Associated with Lower Risk of Ovarian Cancer   New approach to old test may detect ovarian cancer   Ovarian cancer survival influenced by MD specialty   2 reproductive factors are important predictors of death from ovarian cancer   Researchers identify genes that may help in ovarian cancer diagnosis and prognosis   Abdominal chemotherapy boosts survival in ovarian cancer patients   Goodness of milk ‘offset by ovarian cancer risk’   Low dose naltrexone (LDN): Harnessing the body’s own chemistry to treat human ovarian cancer   Ovarian cancer patients survive longer with BRCA2 mutated in tumors   Family breast cancer history ups ovarian cancer risk   Biological diversity of ovarian cancer lessens value of screening   Processed meat linked to higher ovarian cancer risk   Late-Stage Ovarian Cancer Therapy Shows Promise in Phase I Trial   New Antibody Offers Hope for Treating Ovarian, Breast Cancer   New Treatment Implications for Ovarian Cancer Unveiled

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]